Polyclinique De Limoges — Clinical Trial Site

38 Registered trials

13 Currently recruiting

Organisation

Polyclinique De Limoges

Location

Limoges Cedex I, France

Identifier

ORG-100044277

Address

18 Rue Du General Catroux, 87039, France

Departments

#40022: Rheumatology
Cabinet d’Algologie – Polyclinique Chenieux
Centre satellite Clinique Emailleurs - Colombier
Department of Medical Oncology
Department of Oncology
François Chénieux
Médecine Générale -Douleur
Medical Oncology
N/A
Oncologie
Oncologie médicale
Oncologie Radiothérapie
oncology
Oncology-Radiotherapy
Radiotherapy
Radiotherapy Oncology
Rhumatologie
Service d'Oncologie Médicale
Service oncologie radiothérapie
Urology

Clinical trials at this site (38)

Search interface

NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Locally recurrent unresectable or metastatic TNBC with 5 2025-07-08
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting

2024-517423-40-00 Metastatic Castration-Resistant Prostate Cancer 5 2025-06-23
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Patients with localised prostate cancer and high-risk f 5 2025-02-17
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatel… Recruiting

2024-510772-20-00 Rectal cancer locally advanced with microsatellite unst 4 2025-02-06
Combination of baricitinib and anti-TNF in rheumatoid arthritis Recruiting

2024-511442-39-00 Rheumatoid arthritis (RA) 5 2025-02-05
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-507482-26-00 Castrate-resistant prostate cancer with oligometastases 5 2024-10-04
A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt… Recruiting

2023-507684-19-00 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Can 5 2024-07-24
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting

2023-503317-29-00 Metastatic renal cell carcinoma (mRCC) 5 2024-04-12
Capsaicin 179 mg patch versus oral Duloxetine in patients with chemotherapy-induced peripheral neuropathy: a phase 3 randomized multicentric… Recruiting

2023-504618-31-00 Chemotherapy induced peripheral neuropathy (CIPN) 5 2023-10-20
A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer (PEACE 4) Recruiting

2023-508072-11-00 Castration-resistant prostate cancer 5 2019-06-26
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Recruiting

2024-512173-27-00 Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible f 5 2019-03-21
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part… Ended

2023-506146-23-00 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the 4 2025-11-17
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intraves… Ended

2023-507685-10-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2024-05-30
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended

2023-507333-17-00 HER2-low, Hormone Receptor Positive, Metastatic Breast 5 2024-04-15
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
Patient Preference Study of SC Pembrolizumab versus IV Pembrolizumab with hyaluronidase (MK-3475A) in multiple cancer types Ended

2023-506017-22-00 Melanoma, Renal Cell Carcinoma, Non-small cell lung can 4 2024-02-16
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended

2022-502593-17-00 Locally advanced or metastatic hormone receptor (HR)-po 5 2023-09-19
Durvalumab (immunotherapy) maintenance after thoracic chemoradiotherapy (CRT) in frail small cell lung cancer patients whose disease is limi… Ended

2024-512224-11-00 Histologically confirmed frail Limited Disease Small Ce 4 2023-03-24
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23
Treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor in mRCC patients that has… Ended

2024-514644-93-00 Metastatic renal cell carcinoma (mRCC) with a good or o 5 2022-12-09
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended

2024-514480-26-00 Post-menopausal women with localized luminal A breast c 4 2022-10-12